Showing results (11-20 of 177) with videos related to

Sort By:
Pageof 18
Molecular and Cellular Biology|May 31, 2012
Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptorChristine Helsen, Vanessa Dubois, Annelien Verfaillie, et al.
Endocrine-Related Cancer|March 19, 2014
Androgen receptor antagonists for prostate cancer therapyChristine Helsen, Thomas Van den Broeck, Arnout Voet, et al.
Nature Reviews. Urology|September 17, 2014
Emerging mechanisms of enzalutamide resistance in prostate cancerFrank Claessens, Christine Helsen, Stefan Prekovic, et al.
Plos One|March 4, 2014
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell linesLien Spans, Christine Helsen, Liesbeth Clinckemalie, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2018
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agentsKonstantina Karypidou, Sergio R Ribone, Mario A Quevedo, et al.
The Journal of Steroid Biochemistry and Molecular Biology|February 4, 2024
Discovery of a novel androgen receptor antagonist, MEL-6, with stereoselective activity and optimization of its metabolic stabilityChristine Helsen, Konstantina Karypidou, Joice Thomas, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 11, 2024
Structural mechanism underlying variations in DNA binding by the androgen receptorXiao Yin Lee, Wout Van Eynde, Christine Helsen, et al.
Molecular Cancer Therapeutics|October 11, 2022
Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor InhibitorsChristine Helsen, Tien T Nguyen, Xiao Yin Lee, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 12, 2020
A Mechanistic High-Content Analysis Assay Using a Chimeric Androgen Receptor That Rapidly Characterizes Androgenic ChemicalsAdam T Szafran, Michael J Bolt, Caroline E Obkirchner, et al.
Biomed Research International|April 5, 2014
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingThomas Van den Broeck, Steven Joniau, Liesbeth Clinckemalie, et al.
Pageof 18